PURE Bioscience, Inc. (PURE)
OTCMKTS · Delayed Price · Currency is USD
0.0468
-0.0079 (-14.44%)
Dec 18, 2025, 1:52 PM EST

PURE Bioscience Statistics

Total Valuation

PURE Bioscience has a market cap or net worth of 6.12 million. The enterprise value is 11.36 million.

Market Cap6.12M
Enterprise Value 11.36M

Important Dates

The last earnings date was Friday, December 12, 2025.

Earnings Date Dec 12, 2025
Ex-Dividend Date n/a

Share Statistics

PURE Bioscience has 111.89 million shares outstanding. The number of shares has increased by 0.01% in one year.

Current Share Class 111.89M
Shares Outstanding 111.89M
Shares Change (YoY) +0.01%
Shares Change (QoQ) +0.00%
Owned by Insiders (%) 41.26%
Owned by Institutions (%) n/a
Float 65.73M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 2.60
PB Ratio -1.10
P/TBV Ratio n/a
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings -5.23
EV / Sales 4.83
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 0.37

Current Ratio 0.37
Quick Ratio 0.26
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -6.11

Financial Efficiency

Return on Equity (ROE) n/a
Return on Assets (ROA) -119.91%
Return on Invested Capital (ROIC) -1,756.94%
Return on Capital Employed (ROCE) 102.58%
Revenue Per Employee 196,167
Profits Per Employee -181,167
Employee Count12
Asset Turnover 2.23
Inventory Turnover 5.99

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -28.57% in the last 52 weeks. The beta is 0.51, so PURE Bioscience's price volatility has been lower than the market average.

Beta (5Y) 0.51
52-Week Price Change -28.57%
50-Day Moving Average 0.06
200-Day Moving Average 0.07
Relative Strength Index (RSI) 52.06
Average Volume (20 Days) 62,265

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) 0.19

Income Statement

In the last 12 months, PURE Bioscience had revenue of 2.35 million and -2.17 million in losses. Loss per share was -0.02.

Revenue2.35M
Gross Profit 1.43M
Operating Income -2.02M
Pretax Income -2.17M
Net Income -2.17M
EBITDA -2.06M
EBIT -2.02M
Loss Per Share -0.02
Full Income Statement

Balance Sheet

The company has 434,000 in cash and 5.68 million in debt, giving a net cash position of -5.24 million or -0.05 per share.

Cash & Cash Equivalents 434,000
Total Debt 5.68M
Net Cash -5.24M
Net Cash Per Share -0.05
Equity (Book Value) -5.55M
Book Value Per Share -0.05
Working Capital -1.98M
Full Balance Sheet

Cash Flow

Operating Cash Flow -1.76M
Capital Expenditures n/a
Free Cash Flow n/a
FCF Per Share n/a
Full Cash Flow Statement

Margins

Gross margin is 60.66%, with operating and profit margins of -85.98% and -92.35%.

Gross Margin 60.66%
Operating Margin -85.98%
Pretax Margin -92.35%
Profit Margin -92.35%
EBITDA Margin -87.43%
EBIT Margin -85.98%
FCF Margin n/a

Dividends & Yields

PURE Bioscience does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -0.01%
Shareholder Yield -0.01%
Earnings Yield -35.52%
FCF Yield n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

The last stock split was on August 15, 2012. It was a reverse split with a ratio of 0.125.

Last Split Date Aug 15, 2012
Split Type Reverse
Split Ratio 0.125

Scores

PURE Bioscience has an Altman Z-Score of -169.47 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -169.47
Piotroski F-Score 3